IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
FIRST BIOMARKER ANALYSES FROM A PHASE III, RANDOMISED, OPEN-LABEL, FIRST-LINE STUDY OF ERLOTINIB VERSUS CARBOPLATIN (CBDCA) PLUS GEMCITABINE (GEM) IN CHINESE PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR ACTIVATING MUTATIONS (OPTIMAL, CTONG 0802)
Wu, Y-L.1; Zhou, C.2; Chen, G.3; Feng, J.4; Liu, X.5; Wang, C.6; Zhang, S.7; Wang, J.8; Zhou, S.2; Ren, S.2; OPTIMAL Investigators
刊名ANNALS OF ONCOLOGY
2010-10-01
suppl.8页:6-6
收录类别SCI ; ISTP
文章类型Meeting Abstract
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
语种英语
WOS记录号WOS:000283115900015
引用统计
被引频次:7[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64625
专题北京大学临床肿瘤学院
作者单位1.Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
2.Tongji Univ, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
3.Harbin Med Coll, Canc Hosp, Harbin, Peoples R China
4.Jiangsu Prov Canc Hosp, Nanjing, Peoples R China
5.Acad Mil Med Sci, Hosp 307, Beijing, Peoples R China
6.Tianjin Canc Hosp, Tianjin, Peoples R China
7.Beijing Chest Hosp, Beijing, Peoples R China
8.Peking Univ, Sch Oncol, Beijing Canc Hosp, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Wu, Y-L.,Zhou, C.,Chen, G.,et al. FIRST BIOMARKER ANALYSES FROM A PHASE III, RANDOMISED, OPEN-LABEL, FIRST-LINE STUDY OF ERLOTINIB VERSUS CARBOPLATIN (CBDCA) PLUS GEMCITABINE (GEM) IN CHINESE PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR ACTIVATING MUTATIONS (OPTIMAL, CTONG 0802)[J]. ANNALS OF ONCOLOGY,2010,suppl.8:6-6.
APA Wu, Y-L..,Zhou, C..,Chen, G..,Feng, J..,Liu, X..,...&OPTIMAL Investigators.(2010).FIRST BIOMARKER ANALYSES FROM A PHASE III, RANDOMISED, OPEN-LABEL, FIRST-LINE STUDY OF ERLOTINIB VERSUS CARBOPLATIN (CBDCA) PLUS GEMCITABINE (GEM) IN CHINESE PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR ACTIVATING MUTATIONS (OPTIMAL, CTONG 0802).ANNALS OF ONCOLOGY,suppl.8,6-6.
MLA Wu, Y-L.,et al."FIRST BIOMARKER ANALYSES FROM A PHASE III, RANDOMISED, OPEN-LABEL, FIRST-LINE STUDY OF ERLOTINIB VERSUS CARBOPLATIN (CBDCA) PLUS GEMCITABINE (GEM) IN CHINESE PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR ACTIVATING MUTATIONS (OPTIMAL, CTONG 0802)".ANNALS OF ONCOLOGY suppl.8(2010):6-6.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wu, Y-L.]的文章
[Zhou, C.]的文章
[Chen, G.]的文章
百度学术
百度学术中相似的文章
[Wu, Y-L.]的文章
[Zhou, C.]的文章
[Chen, G.]的文章
必应学术
必应学术中相似的文章
[Wu, Y-L.]的文章
[Zhou, C.]的文章
[Chen, G.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。